Science News from #ACC22

Jump to another day's coverage: Saturday | Sunday  |  Monday

Top Late-Breaking Science from ACC 2022

AHA experts Amit Khera, MD, MSc, FAHA, Alanna Morris, MD, MSc, FAHA, Kathryn Lindley, MD, and Chiadi Ndumele, MD, PhD, MHS comment on some of the top late-breaking clinical trial science from ACC 2022.

Selected science from Saturday, April 2

2022 Guidelines for the Management of Heart Failure

Writing Group Chair Paul Heidenreich, MD, MS and Vice Chair Biykem Bozkurt, MD, PhD, FAHA, review some of the key changes reflected in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

CHAP Trial: Antihypertensive Therapy For Mild Chronic Hypertension and Pregnancy Outcomes: A Pragmatic Multicenter RCT

Alan Tita | University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL

Please download the PowerPoint for accessibility and viewing

Also published on Saturday

FAME 3: Quality of Life After Fractional Flow Reserve-Guided PCI Compared with Coronary Bypass Surgery
William F. Fearon | Stanford University, Stanford, CA, et al.
Published in Circulation

Selected science from Sunday, April 3

IVVE: Randomized Controlled Trial Of Influenza Vaccine In Patients With Heart Failure To Reduce Adverse Vascular Events

Mark Loeb | McMaster University, Hamilton, Canada

Download the PowerPoint slide for readability and accesibility.

Also published Sunday

TRANSLATE-TIMI 70: Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol
Brian A. Bergmark | Brigham and Women's Hospital, Harvard Medical School, Boston, MA, et al.

Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial
Paolo Della Bella | San Raffaele University-Hospital, Milan, Italy, et al.

Selected science from Monday, April 4

POISE-3: The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Maura Marcucci | McMaster University, Hamilton, ON, Canada

Thumbnail photo of POISE-3 Results. For accessibility and details, please download the PowerPoint.

Also published Monday

ADAPT-TAVR: Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial
Duk-Woo Park | University of Ulsan College of Medicine, Seoul, Korea, et al.

CHOCOLATE TOUCH: A Randomized Trial of Chocolate Touch Compared with Lutonix Drug-Coated Balloon in Femoropopliteal Lesions
Mehdi H. Shishehbor | University Hospitals Harrington Heart and Vascular Institute, Cleveland, OH, et al.